Introduction
Resistance to anticancer drugs is a common problem faced in the treatment of cancer. Over the past decades, research has shown that some ABC transporters play an important role in the resistance to anticancer, anti-inflammatory, and antiviral drugs [1] [2] [3] [4] . As a result of active transport of structurally related and unrelated drug compounds across membranes, members of the ABCB, -C, and -G families have been recognized for their roles in the onset and maintenance of MDR [1, 4, 5] . Many timely reviews have discussed the role of ABC transporter family members in MDR, their typical drug substrates, transporter antagonists, general tissue distribution, and association with diseases (overview in Table 1 ) [1, 3, 4, 6 -9] . Less attention has been given to the expression of these transporters on immune cells and their putative involvement in immune processes as a result of the active secretion of inflammatory mediators such as PGs (i.e., S-PGA 1 -GSH, PGE 1 , PGE 2 , PGF 2␣ ), LTs (i.e., LTB 4 , LTC 4 , LTD 4 ), S1P, sulfatides, and cyclic nucleotides (cAMP, cGMP) [10, 18] . A detailed overview of the physiological substrates and substrate affinities (Km) for various ABC transporters is provided in Table 2 . The relevance of ABC transporters for immune functions raises the issue immediately of how the combined administration of therapeutic drugs and ABC transporter antagonists would influence the survival and physiological functions of immune cells during treatment. This is of particular importance in cancer treatment, as these patients are already immunosuppressed often as a result of the cancer environment and chemotherapy treatment. On the other hand, the presence of these transporters on immune effector cells could be involved in the onset or refractoriness of autoimmune diseases by the secretion of proinflammatory mediators or by negatively influencing the (long-term) treatment of autoimmune diseases such as RA with immunosuppressing drugs such as NSAID or corticosteroids, as these have also been described to be substrates of ABC transporters [3] .
An immune reaction can be divided in an antigen-independent innate response [64] and an antigen-specific adaptive response [65] . Immune effector cells that belong to the innate response are NK cells, granulocytes, and APCs such as M and DC. These cells are responsible for neutralization of pathogens or direct killing of pathogen-infected cells and the production of chemokines and cytokines to attract cells of the adaptive immune response such as T and B cells, which can eliminate infected cells via cell-cell contact or secreted antibodies. In this review, we evaluate the possible physiological roles of MDRrelated ABC transporters on immune effector cells based on reports about their expression patterns and immune-related substrates. In addition, possible therapeutic consequences and appli- cations for autoimmune diseases such as RA on the one hand and cancer on the other will be discussed. Figure 1 gives a schematic overview of the expression of ABC transporters on different subsets of immune effector cells, which will be discussed in further detail in the paragraphs below.
ABC TRANSPORTERS AND IMMUNE CELLS

Physiological ABC transporter substrates related to the immune response
Next to bile acids, folates, and porphyrins, several small proinflammatory molecules have been described to be substrates for ABC transporters. Groups of such molecules are eicosanoid lipid mediators such as PGs and LTs [96] and sphingolipids as mentioned above (Table 2 and Fig. 2 ) but also steroids or tripeptides such as GSH [97] . The cysteinyl LTC 4 , which is derived from arachidonic acid, exerts a proinflammatory effect on inflammatory cells [98] by facilitating the migration of immune cells to lymph nodes [19, 81] . LTC 4 is the GSH-conjugated form of LTA 4 and has been reported to be transported by MRP1 [28] , MRP2 [40] , MRP3 [43] , MRP4 [45] , MRP6 [54] , MRP7 [55] , and MRP8 [56] with substrate affinities in the nanomolar-submicromolar range (Table 2 ). MRP1 has also been implicated in the transport of LTD 4 and LTE 4 , which are extracellular, metabolized forms of LTC 4 [28] , and MRP4 was shown to transport LTB 4 [45] , which is the hydrolyzed form of the precursor LTA 4 . The other group of eicosanoids, the PGs, are de novo-synthesized upon stress, cytokine-or growth factormediated stimulation, or other stimuli [96] . Different ABC [46] , and MRP2 can export S-PGA 1 -GSH [41] . The tripeptide GSH (L-y-glutamyl-L-cysteinyl-glycine) is used for various cellular detoxification pathways, and several ABC transporters transport GSH or GSH S-conjugates or require cotransport of GSH to transport specific drug substrates such as alkylating agents (Table 1) [29, 97, 99] . Other key inflammatory components transported by MDR transporters are PAF, which is secreted by P-gp [20] , the cyclic nucleotides cGMP and cAMP transported by MRP4, MRP5, and MRP8 [47, 57, 100] , S1P transported by P-gp [19] or MRP1 [30] (Fig. 2) , and steroids, which are potential substrates for P-gp, MRP4, and BCRP [1, 21, 31, 58, 101] .
A controversial issue remains whether MDR transporters are involved in the secretion of (pro)-inflammatory cytokines and chemokines of relatively low molecular mass for such molecules (5-17 kD). Potential protein substrates for MDR transporters could be proteins that are not secreted through the classical exocytic pathway and lack a hydrophobic leader peptide. These proteins, also referred to as leaderless proteins, are secreted through a distinct secretion pathway, in which ABC family A members play a role, rather than the ABCB/C/G (MDR-related) family members [102, 103] . Over the last decade, several studies have postulated that MDR proteins, such as P-gp, could function as efflux transporters of cytokines such as TNF-␣, ILs (IL-2, IL-4, IL-12) [104, 105] , and IFN-␥ [83, 106] and that P-gp inhibition could reduce the secretion of several cytokines [106 -108] . However, in vivo models of Abcb1 a/b knockout mice revealed no differences in cytokine profiles compared with their wild-type counterparts [109] . These conflicting data and the fact that ABC transporters such as the TAP (ABCB2/3) are only able to transport small (oligo) peptides of up to 40-mer residues [26, 110] do not seem compatible with a direct role in the transport of cytokines with molecular masses of up to 17 kD. Nonetheless, it may be possible that by extruding some relevant physiological substrates, alterations in cytokine secretion may result as secondary effects. Zhang et al. [111] showed that MRP1 expression is induced upon T cell activation and that inhibition of MRP1 activity with the antagonist MK-571 resulted in reduced secretion of IFN-␥. As MRP1 inhibition was accompanied by suppression of genes involved in IFN-␥ secretion, it was suggested that MRP1 inhibition influences IFN-␥ secretion only indirectly, i.e., as a result of increased intracellular retention of a nuclear hormone receptor agonist. A different link between ABC transporters and cytokines comes from studies showing that certain cytokines can induce ABC transporter expression [112, 113] .
HSCs
HSCs are the precursors from which all immune cells derive [114] . ABC transporters are believed to have a protective role in HSCs, thus potentially presenting a problem in the treatment of (hematological) malignancies, as cancer stem cells expressing these transporters can escape chemotherapy treatment [115] . Although HSCs were described to express P-gp, MRP1, and MRP4 [66 -68, 116] , the expression of BCRP was most pronounced and has received the most attention [69] . No functional studies have been reported to shed light on the relative differential importance of P-gp, MRP1, and MRP4 in protecting HSC against toxic components. Within HSC, BCRP was identified as the transporter responsible for the so-called side-population phenotype by extrusion of the dye Hoechst 33342 [93] . Despite its presence on stem cells, BCRP knockout mice displayed no alteration in hematopoiesis nor was hemato- [59, 69, 117] . As the expression of BCRP was found to decrease upon lineage commitment, the transporter was hypothesized to play a selective role in uncommitted, pluripotent stem cells [118] . Notwithstanding this fact, more recent studies described BCRP expression in distinct, committed cells, such as erythrocytes [93] , plasma cells [94] , and human skin DC (R. van de Ven, Jelle Lindenberg, Anneke Reurs, Hester van Cruÿsen, R. J. Scheper, G. Jansen, T. D. de Gruijl, unpublished observation.). Therefore, the currently prevailing concept is that BCRP protects the HSC primarily as well as some other specific cell types against endogenous and exogenous toxins, such as porphyrins, under low oxygen conditions [59, 119, 120] . Future studies may possibly reveal other distinct physiological functions of BCRP.
Monocytes and M
M originate from monocytes and are known for their phagocytic capabilities and their important role in the innate immune response [121] . Thus far, little is known about the physiological functions of ABC transporters on human M. Only the role of ABCA1 and ABCG1 in cholesterol efflux and homeostasis has been fully characterized in M [122] . The involvement of MDR transporters in immunological functions of M has been studied primarily in mice, where the MRP inhibitors MK-571 and probenecid reduced zymosan-induced peritonitis [123] . It has been suggested that MRP1 and other MDR transporters are involved in proinflammatory reactions, possibly through the secretion of proinflammatory mediators such as LTC 4 by M. Supportive data are available from Mrp1 knockout mice that exhibited a decreased response to an inflammatory stimulus [124, 125] . Primary human monocytes were found to express low but distinct levels of MRP1-7 mRNA, and upon M differentiation, the mRNA expression levels of these transporters were increased together with de novo mRNA synthesis of P-gp and BCRP [72, 73, 87] . Furthermore, it was shown that inhibition of MRP1 activity did not interfere with human monocyte-to-M differentiation [73] . Finally, high expression of BCRP and moderate expression of MRP1 were found on M in synovial tissue of RA patients [88] . Notably, high BCRP expression on M in the synovial sublining was associated with a diminished response to the antirheumatic drugs methotrexate and leflunomide [88] .
DC
The most potent APCs are DC, which are often considered as the bridge between the innate and adaptive response [126] . DC can process and present exogenous and endogenous proteins efficiently on MHC-I and -II molecules. For MHC-I-mediated antigen presentation, the ABC transporter family members TAP1/2 are essential [27] . Within the DC subsets, ABC transporter expression has been analyzed on interstitial DC and LC, but information is lacking for plasmacytoid DC. In vitro-cultured DC and human skin DC can express P-gp [83, 84, 108] , but expression levels can be rather low [32, 85] . P-gp activity seems important for the migration of human skin DC to the lymphatic vessels, as P-gp neutralizing antibodies and the P-gp antagonist Verapamil reduced migration of DC and retained the DC within the epidermis [83] . It remains unclear which physiologic P-gp substrate(s) actually drive this DC migration. Two candidates are PAF [20] and the sphingolipid metabolite S1P, which was reported to play a role in T lymphocyte migration [19] . Conceptually, a model for T cell homing to the lymph node might involve S1P transport by P-gp and LTC 4 transport by MRP1. As MRP1 is expressed by DC [32, 84, 85] and is involved in DC migration through the transport of LTC 4 [28, 81] , a similar model could apply for lymph node migration of DC [127] . A direct contribution of MRP1 in DC migration was confirmed in Mrp1 knockout mice, which required the exogenous addition of LTC 4 or its derivative LTD 4 to restore DC migration [81] . In the human setting, other ABC transporters such as MRP4 or MRP5 [128] could also play a role in DC migration. MRP4, recently reported to be expressed in epidermal and dermal skin DC [70] , can also transport PGE 2 , LTB 4 , LTC 4 , and cyclic nucleotides such as cAMP and cGMP [46, 48] . A functional association was revealed by the observation that inhibition of MRP4 or MRP4 expression down-regulation by RNA interference reduced human skin DC migration [70] . However, addition of PGE 2 , LTB 4 , LTD 4 , or a cGMP analog could not restore migration [70] , as was shown for LTC 4 in the Mrp1 knockout mice [81] . So, conceivably, a different substrate is involved. In mice, the absence of Mrp4 did not interfere with DC migration from skin or the generation of a proper antigen-specific immune response [129] , suggesting interspecies differences for the functions of ABC transporters on immune cells.
In addition to a role in DC migration, MRP1 also appeared of relevance in DC differentiation [32] . Initial studies by Laupeze et al. [85] , using a low-affinity MRP1 antagonist (indomethacin), showed a significant reduction in CD40 expression on DC. More powerful inhibition of MRP1 activity by MK-571 or probenecid during DC differentiation from monocytes (MoDC) or from the acute myeloid leukemia-derived cell line MUTZ3 [130, 131] resulted in a markedly impaired differentiation toward interstitial DC and LC [32, 73] . Functionally, these MRP1-blocked DC secreted less IL-12 and were impaired in their capacity to stimulate T cell proliferation [32] . However, as these effects appeared to be LTC 4 -independent, it is still unclear which other MRP1 substrate could play a role in this process. Effects of P-gp inhibition on DC differentiation remain unclear, as Pendse et al. [108] reported an inhibitory effect, and studies from our laboratory showed no effect of P-gp inhibition on the differentiation of MoDC [32] . Discrepancies between these studies might be explained by the different concentrations of the P-gp inhibitor used and different expression levels of P-gp on the donor-derived MoDC. Also, Pendse et al. [108] reported that inhibition of P-gp in MoDC or during monocyte activation with LPS resulted in reduced secretion of IL-12. Recently, we found that BCRP is expressed by human skin DC and that overexpression of BCRP on CD34 ϩ DC precursor cells resulted in accelerated LC differentiation and endogenous TGF-␤-dependent, LC-specific CD1a 
T cells
The expression of ABC transporters on T cells has been studied, revealing active P-gp and MRP1 [71, 77, 78, 132] . Moreover, a correlation was found between high P-gp expression on T cells of RA patients and the lack of response to steroid treatment [133] [134] [135] . Different T cell subsets or activation states are associated with distinctive patterns of P-gp expression and activity, which could be relevant for their functions. CD8 ϩ T cells were found to have high P-gp activity, whereas low P-gp activity was detected in CD4 ϩ T cells [66, 71] . Ludescher et al. [71] showed that naive CD8 ϩ T cells exhibited higher P-gp activity than CD8 ϩ memory T cells. As mentioned, P-gp expression was shown to be important for S1P transport in T lymphocyte homing [19] . In Tregs, expression of ABC transporters has not yet been reported, but it is known that Tregs are extremely sensitive to chemotherapy [136] , suggesting that these cells probably express minimal or low levels of drug efflux transporters. As the immune-regulatory ABC transporter substrates identified thus far generally promote a proinflammatory environment, the hypothesis that Tregs express only low levels of ABC transporters should be tested.
Although P-gp has been widely studied in T cells, some apparent discrepancies were reported regarding its expression and function. For example, some studies report an increase in P-gp expression upon T cell activation [71, 95] , whereas other studies reported a decrease [137] [138] [139] . Other apparent inconsistencies relate to the function of P-gp in the process of aging; some studies indicated that P-gp activity is decreased upon aging [140 -142] and may thereby contribute to a decrease in T cell cytolytic activity, and others showed an increase in P-gp activity [143] or no effect at all [144] . A similar controversy was found with respect to Mrp1 expression on activated murine Th1 cells; Mrp1 was identified initially as a specific Th1 activation marker, as treatment with MK-571 could block activation [145] , but a later study in Mrp1 knockout mice showed normal Th1 activation [146] , suggesting that the MK-571 effect was Mrp1-unrelated. Given normal in vivo antigen-specific responses in mice lacking Mrp4 expression [129] , it seems unlikely that MK-571 inhibition of Mrp4 activity is involved in Th1 activation.
B cells
Originating from the bone marrow, B cells can develop into plasma cells or memory B cells, which are key regulators of the humoral immune response. Limited data are available about the expression and function of ABC transporters on B cells. In cancerous plasma cells, i.e., multiple myeloma, P-gp activity was linked to therapy resistance to vincristine, doxorubicin, and glucocorticoids [147] . In healthy individuals, P-gp activity was shown to be reduced upon B cell activation and differentiation into memory B cells [74 -76, 141, 148] . In addition to P-gp, functionally active BCRP was found recently to be present on normal human plasma cells [94] , and BCRP activity was associated with an unfavorable therapy outcome in multiple myeloma [149] .
NK cells
NK cells play a central role in the host defense against viral infections. NK cells have been described to possess the highest level of functional P-gp compared with other leukocyte populations [80] . Ludescher et al. [71] reported that inhibition of P-gp activity in NK cells resulted in reduced cytotoxicity, suggesting that P-gp is involved in the secretion of cytotoxic compounds by NK cells. The authors discussed that P-gp might have a role in the secretion of perforins, as previous reports had also found a relation between P-gp activity and cytotoxicity of CD8 ϩ T cells [95, 150] . However, the MW of perforins (ϳ50 kD) by far exceeds size limits for most common substrates transported by these transporters (MW: 1-2 kD). Studies by N'cho et al. [151] and Takahashi et al. [152] also supported a role for P-gp in NK cell cytotoxicity. The latter study proposed a role for P-gp in regulating the pH in lysosomes in NK cells. Beside P-gp protein expression, mRNA expression of MRP1 and MRP2 was also described in NK cells [79] . Protein expression levels and the functional relevance of these transporters for NK cells remain to be established.
ABC TRANSPORTER EXPRESSION REGULATION AND LINKS TO IMMUNE ACTIVATION
Signal transduction pathways involved in DC and immune activation can be linked to expression regulation of ABC transporters, e.g., P-gp, MRP1, and BCRP. Activation of the p38 MAPK pathway by inflammatory cytokines has been linked to human DC maturation and enhanced anti-tumor responses in mice [153, 154] . Inhibition of p38 MAPK resulted in reduced IL12p70 secretion and reduced expression of costimulatory molecules and chemokine receptors by DC, resulting in poor T cell stimulatory and migratory capacities [154, 155] . In tumor cells, inhibition of p38 MAPK was shown to decrease the activation of the transcription factor AP-1 with subsequent down-regulation of P-gp expression [156, 157] . AP-1 also has binding motifs on several other transporters, e.g., MRP1 [158] and BCRP [159] . Beside the p38 MAPK pathway, the PI3K/Akt pathway has also been linked to DC activation, IL-12 secretion by DC, and DC survival [160] . Inhibition of Akt activation has been shown to reduce P-gp and MRP1 expression [161, 162] , and Akt phosphorylation has been reported to be required for translocation of BCRP from the cytoplasm to the plasma membrane [117, 163] . These reports suggest a functional role for ABC transporters during an inflammatory response.
THERAPEUTIC APPLICATIONS FOR ABC TRANSPORTER MODULATION
Autoimmune diseases
In autoimmune diseases, there is a loss of negative selection toward self-antigens, resulting in proliferation of autoreactive T cells and production of autoantibodies by plasma cells. These processes are accompanied by a permanent proinflammatory state of the immune system, reflected by production of proinflammatory cytokines such as TNF-␣, IL-1␤, and IL-6. Al-though some antibody-driven autoimmune diseases such as myasthenia gravis, idiopathic, and thrombotic thrombocytopenic purpura can be self-limiting or potentially treated with ritixumab targeting CD20 on B cells [164, 165] , other autoimmune diseases such as RA require mostly life-long immunosuppressive therapy, targeting different inflammatory cells [166] . Unfortunately, chronic exposure of patients to immunosuppressive agents often leads to the induction of drug resistance. From this viewpoint, different roles for MDR transporters in the pathophysiology of autoimmune diseases can be hypothesized. First, as described in the previous section, MDR transporters can transport proinflammatory substrates that may trigger the immune system and facilitate attraction of immunecompetent cells to the site of inflammation. Second, inflammatory cytokines can induce expression of ABC transporters, thereby possibly causing persistence of the response as a result of enhanced secretion of other inflammatory mediators by the ABC transporters. Third, the MDR transporters, which are present on activated immune effector cells, might be associated with baseline resistance to treatment in autoimmune diseases, as it is known that MDR transporters have antiinflammatory drugs among their substrates. Several lines of evidence are available that support this latter role, particularly in the treatment of RA with DMARDs [3] : In vitro studies have shown that several DMARDs, e.g., MTX, chloroquine, and sulfasalazine, are substrates of MDR transporters. Therefore, the therapeutic efficacy of DMARDs can be impaired by the presence of ABC transporters on immune effector cells, leading to persistent inflammation. Furthermore, the use of DMARDs might itself induce the expression of MDR transporters on inflammatory cells [3, 167, 168] . In accordance with these observations, van der Heijden et al. [169] showed that the onset of sulfasalazine resistance in human CEM T cells after prolonged exposure is accompanied by a marked induction of BCRP expression. Sulfasalazine sensitivity could be largely restored in these cells by adding the specific BCRP blocking agent Ko-143 to the culture medium, proving the functional relation of BCRP expression and sulfasalazine resistance. In sulfasalazineresistant T cells, basal levels of TNF-␣ production after stimulation were increased markedly compared with parental T cells, pointing to an enhanced inflammatory state of these cells. Concurrently, TNF-␣ production was blocked less efficiently by sulfasalazine, consistent with BCRP-mediated efflux of this drug [169] . Later, also, in vivo data confirmed BCRP-mediated transport of sulfasalazine, as BCRP was shown to be a major determinant in sulfasalazine absorption and elimination in mice [170] . In addition, certain ABC transporters, such as MRP1-5 and BCRP, can transport different conjugates of folates and anti-folates (Table 2) . It has been well recognized that these transporters may impact the intracellular folate pool size and folate homeostasis under physiological conditions [17] . Also, overexpression of these transporters conferred moderate to marked levels of resistance to various antifolates, such as methotrexate, the cornerstone in the treatment of RA [168] . However, it is important to note that to date, no reports are available in which antifolate-selected cell lines overexpress relevant ABC transporters.
Several clinical studies have been undertaken to investigate the role of ABC transporters in conferring resistance in autoimmune diseases. Some of these studies have shown increased P-gp expression in peripheral blood lymphocytes and T cells from RA patients after DMARD treatment [171] or from therapynonresponsive patients [172, 173] (R. Oerlemans, Ben Dÿk-mans, J. W. van der Heijden, Willem Lens, Anneke Reurs, G. Jansen, R. van de Ven, Godefridus Peters, Yehuda Assaraf, R. J. Scheper, G. Jensen, unpublished results.). Studies by Jorgensen et al. [174] revealed high levels of P-gp protein expression in rheumatoid synovium in five out of 16 patients. In our laboratory, we found expression and functional activity of P-gp in peripheral blood lymphocytes of healthy controls (nϭ10) and RA patients (nϭ21). P-gp activity was significantly higher in DMARD-treated patients compared with DMARD naïve patients, in line with previous observations [171] [172] [173] . Also, increased mRNA expression for MRP1 and MRP4 was found in peripheral blood lymphocytes of RA patients compared with controls, the latter being related to poor response to DMARD therapy. Moreover, BCRP was shown to be a dominant transporter in monocyte-derived M, with its expression significantly higher in RA patients compared with controls [175] . In accordance with this finding, we also showed that BCRP is expressed on M in inflamed synovial tissue from RA patients [88] . High BCRP expression was positively correlated with disease activity and unresponsiveness to the antiarthritic drugs MTX and leflunomide (both known BCRP substrates). In the same study, MRP1 expression was observed on T cells organized in aggregates in synovial tissue of one-third of the studied RA patients. Expression of P-gp was below limits of detection in RA synovial tissue, consistent with the findings of Jorgensen et al. [174] .
Expression of MDR transporters in autoimmune diseases is not only restricted to RA. In other autoimmune diseases, such as myasthenia gravis, thrombocytopenic purpura, and systemic lupus erythematosus, expression of P-gp was associated with diminished efficacy of steroids [135, 176 -178] . These data are indicative of a role of P-gp and other MDR transporters in conferring resistance to immunosuppressive agents in autoimmunity. On the other hand, increased expression of these transporters may also play a causative role in persistent inflammation, as described earlier, as a result of enhanced transport of proinflammatory substrates such as LTC 4 , PAF, and S1P.
Currently, no clinical studies have been initiated to explore potential beneficial effects of MDR antagonists in treatment protocols for autoimmune diseases. In theory, autoimmune diseases would benefit optimally from the use of MDR transporter antagonists, as they would block the secretion of proinflammatory ABC transporter substrates and in parallel, prevent resistance against anti-inflammatory drugs. From this perspective, the concomitant use of the NSAID drug sulindac might enhance therapy with immunosuppressive agents, as it is known to block MRP1 [179] and MRP4 [45] activity. It is of interest to note that beyond sulindac, several other NSAIDs also harbored MRP1 antagonistic activity [179] . Clearly, the role of MDR transporters other than P-gp and immune-effec-tor cells other than T lymphocytes warrants further exploration.
Cancer
In the treatment of cancer, chemotherapy is the third-most used option next to surgery and radiotherapy. It is recognized that chemotherapy regimens are often hampered by the acquisition of chemo-resistance during treatment. Over the past decades, the discovery of the involvement of ABC transporters in the resistant phenotype initiated extensive research for a potent ABC transporter antagonist to overcome drug resistance. However, at that time, little was known about the putative physiological functions of these transporters. Nowadays, several of these transporters have been linked to physiologically important processes, e.g., functions in the kidneys and the liver, protection of the BBB, placenta against endogenous (and exogenous) toxic compounds, and the involvement of the secretion of substrates important for the optimal functioning of immune cells. It therefore seems obvious that clinicians and researchers should be cautious with inhibiting the activity of these transporters, as this could evoke unwanted side-effects. As inhibition of ABC transporters in combination with systemic chemotherapy has proven inefficient and severely toxic, novel strategies should be considered, such as local application of MDR antagonists at the site of the tumor (which of course might not be helpful in metastatic disease) or specific targeting of MDR transporters in tumor cells. With respect to the immune system and cancer, it is established that treatment with chemotherapeutic agents dampens the immune response dramatically, as many immune effector cells are collaterally targeted by this treatment [127] . Patients receiving chemotherapy are therefore susceptible to viral and bacterial infections. Inhibition of MDR-related ABC transporters on top of chemotherapy treatment to bypass MDR could then even enhance this immune-suppression further and increase the risk of infections. It is also appreciated that the immune system is important for antitumor effects. Within the innate immune system, NK cells are known to recognize MHC I down-regulation on tumor cells [180] , which is a trigger for these cells to eradicate the tumor cell. For this, NK cells need functional cytotoxic granules (lysosomes), which may require P-gp activity for functionality [71, 151, 152] . In the adaptive response, APC (and DC in particular) are needed to take up tumor cells and present TAA to T cells. For APC precursors to fully differentiate into DC, they require active MRP1 [32, 73] and perhaps P-gp [108] . Subsequently, the DC need to migrate to the draining lymph nodes to present the TAA and activate T cells. For this migration, the functional activity of P-gp [83] , MRP1 [81] , and MRP4 [70] is critical. For the homing of T cells within the lymph nodes, MRP1 and P-gp are required [19] . Activated T cells subsequently leave the lymph nodes to home to the site of the tumor, where they use P-gp activity to secrete cytotoxic compounds from granules [95, 150] . Inhibition of ABC transporters, in conjunction with suppressive cytokines produced by tumor cells, might therefore block the development of DC completely and stop the presentation of TAA to T cells. Our ever-increasing knowledge about the role of ABC transporters in immune effector cells should be exploited to improve anticancer therapies through enhancement of the expression of ABC transporters on immune cells, whether by drugs, specific targeting by ABC transporter-encoding adenoviruses, or other means. Certainly, more research is warranted to comprehend the full involvement of ABC transporters in the generation of an immune response.
CONCLUDING REMARKS
Over the last decade, accumulating evidence has emerged emphasizing critical functional roles for MDR-related ABC transporters in immune effector cells. This knowledge should be considered and exploited for the development of new strategies for the treatment of autoimmune diseases and cancer. When increased expression of a transporter leads to improvement of an immune response, this could be an interesting tool for combined chemo-immunotherapies in cancer patients, as the affected immune effector cells will gain in functionality and at the same time, will be less prone to toxic side-effects of chemotherapy treatment. Conversely, from the perspective of treatment of autoimmune diseases, it may be beneficial to decrease the expression or functionality of specific transporters on specific subsets of immune effector cells, as this could attenuate the generation of an autoimmune response by hampering immune effector cell differentiation and functionality.
